Effect of Treatment with the PD-1/PD-L1 Inhibitors on Key Health Outcomes of Cancer Patients.
Kyung-In JoungJong Hwa SongKangho SuhSeung-Mi LeeJi Hyun JunTaehwan ParkDong Churl SuhPublished in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2020)
Anti-PD-1/PD-L1 therapy is expected to provide marked survival benefits for patients with cancer. This study demonstrated the potentially beneficial health impacts of utilizing the anti-PD-1/PD-L1 class at the population level. The findings could inform health policy decision makers about cancer care and ultimately enhance population health through rapid access to innovative cancer drugs.